Frank Weinberg, MD, PhD

Cutting-edge therapies can help move the treatment landscape forward, but basic treatment and prevention, such as smoking cessation, are still valuable means of addressing non–small cell lung cancer (NSCLC).

Making treatment for non–small cell lung cancer (NSCLC) accessible to a wide range of the population can help to improve outcomes from and knowledge of the condition.

A panel held during the Institute for Value-Based Medicine event in Chicago on August 14, 2025, included discussions of access to biomarker testing and perioperative treatment in patients with non–small cell lung cancer (NSCLC).